Eye Aging Speed and Your Genetics
Written by the ExomeDNA editorial team. Last reviewed 2026-05-29.
This page contains general information only. For personal health decisions, consult a qualified clinician.
Eye aging speed measures how quickly your retina's biological age advances relative to your chronological age — and a 2023 genome-wide study of longitudinal fundus images confirmed that genetic variants in at least seven loci, including the macular degeneration gene ARMS2 and the Bruch's membrane structural collagens COL4A3 and COL4A4, measurably accelerate this clock. Below: what the science means, which genes are implicated, and evidence-based steps you can take to support long-term retinal health.
What is eye aging speed?
Eye aging speed — formally called eye age acceleration or retinal age acceleration — quantifies the gap between your retina's apparent biological age and your actual chronological age. The measurement comes from deep-learning AI models trained on retinal fundus photographs. These models, sometimes called RetinalAge clocks or retinal biomarker clocks, analyze the fine vascular architecture, disc morphology, and pigment patterns visible through standard fundus photography to generate an estimated biological age. When the model's estimate exceeds your real age, the difference is your eye age acceleration score: a positive number means your retina appears older than expected; zero or negative means it appears younger.
What makes this metric scientifically compelling is that the retina is the only tissue in the human body where blood vessels and neurons can be observed non-invasively in real time. The retinal microvasculature is structurally continuous with the cerebral microvasculature, the choroidal circulation reflects systemic cardiovascular load, and the retinal pigment epithelium (RPE) is one of the most metabolically demanding cell types in the body. Biological aging in the retina therefore reflects aging processes that extend well beyond the eye itself. Studies using retinal age clocks have found that higher acceleration predicts all-cause mortality, cardiovascular events, and cognitive decline independently of standard clinical risk factors.
The trait is graded as detrimental when higher: a higher acceleration score — a retina that looks older than you are — is consistently associated with worse systemic health outcomes. Your ExomeDNA result reflects your polygenic predisposition toward faster or slower retinal biological aging based on variants identified in population-level genome-wide association studies.
The genetics behind eye aging speed
Seven genes authorized by ExomeDNA's scientific curation process contribute to your eye aging speed result. Each acts through a distinct biological mechanism, and together they paint a coherent picture of what drives retinal biological aging at the molecular level.
ARMS2 (age-related maculopathy susceptibility 2) encodes a protein localized to the choroidal extracellular matrix beneath the RPE. ARMS2 is one of the two strongest known genetic loci for age-related macular degeneration (AMD), the leading cause of severe vision loss in adults over 55. In the context of eye age acceleration, ARMS2 variants that confer AMD susceptibility also appear to push retinal AI clocks forward — the same choroidal extracellular matrix disruption that predisposes to AMD manifests as an older-looking retinal fundus even before frank disease develops.
COL4A3 and COL4A4 encode alpha-3 and alpha-4 chains of type IV collagen, which together with COL4A5 form the heterotrimeric collagen networks that give Bruch's membrane its structural integrity. Bruch's membrane is the thin basement membrane layer between the RPE and the choriocapillaris; it supports RPE cell adhesion, regulates nutrient flow to photoreceptors, and is the primary site of drusen deposition — the extracellular debris accumulations that mark early AMD. With normal aging, Bruch's membrane progressively thickens, cross-links, and calcifies, reducing its permeability and the RPE's ability to shed metabolic waste. Rare loss-of-function variants in COL4A3 and COL4A4 cause Alport syndrome, a multi-organ basement membrane disease whose ocular manifestation includes retinal dystrophy. Common variants at these loci modulate Bruch's membrane quality in the general population, influencing how rapidly structural aging proceeds.
ATP6V0A2 encodes the a2 subunit of vacuolar-type H⁺-ATPase, the proton pump that acidifies lysosomes and late endosomes. RPE cells perform one of the most intense phagocytic tasks in the body: every day, each RPE cell ingests and degrades the tips of roughly 30 photoreceptor outer segments shed by the overlying rods and cones. This daily clearance depends on efficient lysosomal acidification. When lysosomal function falters, partially digested lipids and proteins accumulate as lipofuscin, the autofluorescent "biological garbage" whose buildup in RPE cells is a hallmark of retinal aging and a precursor to geographic atrophy. Germline mutations in ATP6V0A2 cause autosomal recessive cutis laxa — a premature systemic aging syndrome affecting connective tissues — directly demonstrating this gene's central role in aging biology. In the retina, common variants that modulate ATP6V0A2 function are thought to influence the rate at which lipofuscin accumulates and, by extension, how quickly the RPE ages.
ALKAL2 encodes ALK and LTK ligand 2, a neurotrophic growth factor that activates the ALK and LTK receptor tyrosine kinases. It is expressed in retinal neurons and is thought to participate in photoreceptor survival signaling. Loss of neurotrophic support during aging is associated with progressive photoreceptor attrition; ALKAL2 variants may modulate the pace at which this occurs.
BAZ2B (bromodomain adjacent to zinc finger protein 2B) is a chromatin remodeling factor involved in epigenetic regulation. Epigenetic drift — the gradual loss of orderly DNA methylation and histone modification patterns — is a core feature of cellular aging. BAZ2B variants may influence how rapidly retinal cells accumulate epigenetic age.
AREL1 (apoptosis resistant E3 ubiquitin protein ligase 1) is an anti-apoptotic ubiquitin ligase that suppresses programmed cell death. In the aging retina, both RPE cells and photoreceptors become progressively more vulnerable to apoptotic stimuli from oxidative stress, accumulated metabolic byproducts, and chronic low-grade inflammation. AREL1 variants that alter the threshold for apoptosis may influence the rate at which retinal cell populations decline over decades.
What the research says
Research base: Moderate. The primary evidence base for this trait comes from a single high-quality 2023 genome-wide association study (Ahadi S et al., Nature Aging, PMID 36975205) that combined longitudinal fundus imaging with genome-wide analysis across a large biobank cohort. This study was the first to demonstrate that retinal biological aging — as measured by deep-learning AI clocks — has a detectable genetic component with loci in biologically plausible pathways. The moderate confidence tier reflects both the scientific plausibility of the identified mechanisms and the limitation that replication in independent large-scale cohorts is still accumulating.
Key quantitative findings from the literature:
- In the Ahadi et al. cohort, retinal age acceleration predicted all-cause mortality with a hazard ratio of approximately 1.02 per year of acceleration (PMID 36975205), a magnitude comparable to established aging biomarkers and statistically independent of chronological age, sex, and conventional clinical risk factors.
- The SNP heritability of eye age acceleration was estimated at approximately 10-15% in the discovery cohort, confirming a meaningful polygenic genetic contribution alongside large environmental and stochastic components.
- Among the identified loci, ARMS2 region variants showed the strongest association signal, consistent with this locus's known role in macular aging biology.
- Retinal age acceleration was associated with higher systolic blood pressure, current smoking status, higher BMI, and lower physical activity levels in the same cohort — factors that overlap substantially with known modifiable influences on macular and cardiovascular aging.
The biological plausibility of the COL4A3/COL4A4 signal is supported by extensive prior literature on Bruch's membrane aging in AMD (independent of this specific GWAS). The ATP6V0A2 mechanism (lysosomal acidification and RPE lipofuscin clearance) is supported by cell biology literature on RPE aging, though its specific role in population-level eye age acceleration genetics awaits further replication.
How eye aging speed affects you
Your retinal biological age reflects a convergence of genetic predisposition, cumulative environmental exposures, and systemic metabolic health. Understanding how this trait manifests in practice helps put your result in context.
Systemic health reflection. Because retinal vasculature is structurally contiguous with cerebral and systemic microvasculature, retinal age acceleration captures not only ocular aging but also cardiovascular and metabolic aging. Those with higher acceleration tend to show earlier signs of microangiopathy, reduced retinal vessel caliber, and subtler changes in optic disc architecture. These changes mirror processes occurring in the brain and kidneys simultaneously.
AMD risk context. The ARMS2 genetic connection means that those with higher polygenic scores for eye age acceleration may also carry elevated genetic susceptibility to AMD. However, these are probabilistic tendencies at a population level. AMD requires decades of cumulative insults — oxidative stress, lipid accumulation in Bruch's membrane, chronic complement activation — and genetic predisposition is one input among many.
Progressive but slow-moving. Retinal biological aging is a decades-long process. Unlike acute conditions, eye age acceleration manifests as gradual shifts in the retinal fundus that accumulate over years. This timeline is both sobering and empowering: the long window between genetic predisposition and clinical manifestation is also the window during which lifestyle modifications can have meaningful impact.
What it does not mean. A higher eye aging speed result does not mean you currently have any retinal disease or that retinal disease is inevitable. Genetic predisposition to faster biological aging operates at a population level across thousands of individuals; individual outcomes depend heavily on modifiable factors and chance. The result is a signal about biological tendencies, not a clinical finding.
Working with your eye aging speed result
The following are evidence-informed steps grounded in the published literature on retinal aging. Consult your ophthalmologist or primary care clinician before making significant changes to supplementation, medications, or screening schedules.
Schedule regular dilated fundus examinations. An ophthalmologist or optometrist examining the fundus through a dilated pupil can detect early drusen, pigmentary changes, and vascular alterations years before symptoms develop. For adults over 40 with any family history of macular degeneration or elevated genetic risk, annual or biennial dilated exams are a reasonable baseline.
Consider the AREDS2 supplement formula if appropriate. The Age-Related Eye Disease Study 2 (AREDS2) established that a specific combination of vitamins C and E, lutein, zeaxanthin, and zinc reduces the risk of progression from intermediate to advanced AMD by approximately 25%. Whether this formula benefits those with elevated genetic risk but no current drusen is not yet established by trial data; discuss with your eye care provider.
Adopt a Mediterranean-pattern diet. Epidemiological evidence consistently associates higher adherence to Mediterranean dietary patterns — rich in leafy greens, colorful vegetables, fish, olive oil, and nuts — with lower rates of AMD progression. Lutein and zeaxanthin (found in dark leafy greens and eggs) concentrate in the macular pigment, where they act as optical filters and antioxidants protecting the RPE and photoreceptors.
Stop smoking, or never start. Cigarette smoking is the single largest modifiable risk factor for AMD, roughly doubling lifetime risk and significantly accelerating retinal biological aging. The Ahadi et al. study found smoking was independently associated with higher retinal age acceleration. The protective effect of smoking cessation is detectable within years of stopping.
Control blood pressure. Hypertension is associated with accelerated retinal vascular aging, thickening of retinal arteriolar walls, and reduced choroidal perfusion. Maintaining blood pressure in a healthy range — through lifestyle measures and, when appropriate, medication — supports retinal microvascular health over decades.
Protect your eyes from ultraviolet light. UV radiation accelerates oxidative damage in the RPE and lens. Wearing sunglasses with UV400 protection, particularly during high-exposure activities, reduces cumulative photochemical stress on retinal tissues.
Manage blood glucose and metabolic health. Chronic hyperglycemia accelerates retinal microvascular aging through glycation of basement membrane proteins (including the type IV collagen networks encoded by COL4A3 and COL4A4) and oxidative stress to the RPE. Maintaining metabolic health through physical activity and dietary quality supports Bruch's membrane integrity over time.
Related traits and genes
Eye aging speed sits within the broader Aging category on ExomeDNA and connects to several adjacent traits and genes in your report.
The ARMS2 gene links this trait to the Age-Related Macular Degeneration Risk trait, where its AMD-specific association is analyzed in greater detail. Understanding both traits together gives a more complete picture of your macular aging biology.
The COL4A3 and COL4A4 collagen genes also contribute to connective tissue integrity traits elsewhere in the ExomeDNA panel, reflecting the systemic importance of basement membrane collagen networks in aging across multiple organ systems including the kidney.
ATP6V0A2's role in lysosomal biology connects to skin aging traits and cellular senescence markers, since lysosomal autophagy capacity is a shared mechanism across multiple tissue aging processes — a reminder that retinal aging does not occur in biological isolation.
Within the Aging category, related traits worth reviewing alongside eye aging speed include biological age acceleration (measured by DNA methylation clocks), skin aging rate, and cardiovascular biological aging — all of which share upstream mechanisms involving oxidative stress, epigenetic drift, and basement membrane integrity that may be reflected in your overall aging genetic profile.
References
- Ahadi S et al. (2023). Longitudinal fundus imaging and its genome-wide association analysis provide evidence for a relationship between retinal aging and systemic diseases. Nature Aging. PMID 36975205.
ExomeDNA genetic results are for wellness and educational purposes only. Consult a clinician for personalized health guidance.